U C B SA (UCB.BR)

UCB.BR on Brussels Stock Exchange

45.99EUR
11:35am EDT
Price Change (% chg)

€1.75 (+3.96%)
Prev Close
€44.24
Open
€44.42
Day's High
€45.99
Day's Low
€44.15
Volume
467,267
Avg. Vol
240,166
52-wk High
€50.24
52-wk Low
€38.01

UCB.BR

Chart for UCB.BR

About

UCB SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia,... (more)

Overall

Beta: 0.51
Market Cap (Mil.): €8,113.90
Shares Outstanding (Mil.): 183.43
Dividend: 0.76
Yield (%): 1.73

Financials

  UCB.BR Industry Sector
P/E (TTM): 35.42 38.06 37.87
EPS (TTM): 1.25 -- --
ROI: 3.11 19.42 18.70
ROE: 5.14 20.10 19.53
Search Stocks

UCB H1 core profit below expectation on sluggish Vimpat sales

BRUSSELS, July 31 - Belgian pharmaceutical group UCB reported first half core profit below expectations due to lower-than-expected sales of epilepsy drug Vimpat and higher research expenses.

31 Jul 2013

UCB says U.S. FDA committee recommends its drug Cimzia for new uses

BRUSSELS - Belgian pharmaceutical group UCB SA said a committee of the U.S. Food and Drug Administration voted in favor of allowing UCB's arthritis drug Cimzia to be used to treat adults with active axial spondyloarthritis.

24 Jul 2013

FDA panel narrowly backs new use of UCB's arthritis drug

- A panel of advisers to the U.S. Food and Drug Administration narrowly recommended approving Belgian drugmaker UCB SA's rheumatoid arthritis drug for an additional indication.

23 Jul 2013

BRIEF-UCB announces new partnership neurology research

BRUSSELS, June 11 - UCB S.A. : * Says to collaborate with crelux and 4sc discovery to meet unmet needs in

11 Jun 2013

UCB suffers as cold weather delays hay fever season

BRUSSELS, April 25 - Belgian drugmaker UCB had a difficult first quarter as cold spring weather in Europe meant fewer hay fever sufferers were buying its allergy medicines, it said on Thursday.

25 Apr 2013

UCB reaches maximum 250 mln euros with retail bond sale

BRUSSELS, March 27 - Belgium-based drugmaker UCB said it has raised the maximum 250 million euros ($321.47 million) it was aiming for by selling a retail bond on the Brussels stock exchange to help refinance its debt.

27 Mar 2013

BRIEF-UCB, Five Prime Therapeutics collaborate

BRUSSELS, March 19 - UCB S.A. : * UCB and Five Prime Therapeutics announce strategic discovery

19 Mar 2013

UCB says had positive trial for Vimpat as monotherapy

BRUSSELS - Belgian pharmaceutical company UCB said on Tuesday its new epilepsy treatment Vimpat had produced promising results in a Phase III trial into its use without other drugs.

05 Mar 2013

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$472.00
Provider: Datamonitor
$175.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks